Spero Therapeutics (SPRO) vs XBiotech (XBIT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
XBiotech (XBIT) has outperformed Spero Therapeutics (SPRO) over the past year, losing 17.0% versus a loss of 45.8%. Over five years, XBIT leads with a -83.4% price change compared with -93.1% for SPRO. Spero Therapeutics is the larger company by market cap ($68.1 million vs $66.8 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | SPRO | XBIT |
|---|---|---|
| Share price | $1.17 | $2.19 |
| Market cap | $68.13M | $66.77M |
| 1-day change | -1.68% | +1.39% |
| YTD return | -49.79% | -8.37% |
| 1-year return | -45.83% | -17.05% |
| 5-year return | -93.13% | -83.42% |
| P/E ratio (TTM) | 8.36 | — |
| Forward P/E | — | 16.85 |
| EPS (TTM) | $0.14 | $-1.48 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.08 | $3.44 |
| 52-week low | $1.08 | $2.09 |
| Distance from 52-week high | -62.01% | -36.34% |
| Average volume | 1.20M | 40.47K |
| Shares outstanding | 58.23M | 30.49M |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- XBIT has outperformed SPRO by 28.8 percentage points over the past year.
SPRO vs XBIT FAQ
Which is bigger, Spero Therapeutics or XBiotech?
Spero Therapeutics (SPRO) is larger, with a market capitalization of $68.13M compared with $66.77M for XBiotech (XBIT).
Which stock has performed better over the past year, SPRO or XBIT?
XBIT returned -17.05% over the past 12 months, compared with -45.83% for SPRO (price return, excluding dividends). Past performance does not predict future results.
Are Spero Therapeutics and XBiotech in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.